FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117579170> ?p ?o ?g. }

• W2117579170 endingPage "34" @default.
• W2117579170 startingPage "29" @default.
• W2117579170 abstract "Background Generic fixed-dose combinations have been prequalified by WHO to treat HIV-infected patients in resource-limited countries. Despite their widespread use they are, however, not yet recommended by some of the major donor agencies owing to scarcity of clinical data on effectiveness, safety, and quality. We aimed to assess these issues for one of the most frequently prescribed treatments in Africa, a generic fixed-dose combination of nevirapine, stavudine, and lamivudine. Methods 60 patients were followed in an open-label, 24-week multicentre trial in Cameroon. All patients received one tablet of the fixed-dose combination drug twice daily. The primary outcome measure was the proportion of patients with viral load less than 400 copies per mL at the end of the study period, in an intention-to-treat analysis. Findings At baseline, 92% of patients (n=55) had AIDS; median CD4 count was 118 cells per μL (IQR 78–167) and median plasma HIV-1 RNA was 104 736 copies per mL (40 804–243 787). The proportion of patients with undetectable viral load (<400 copies per mL) after 24 weeks of treatment was 80% (95% CI 68–89). Median (IQR) change in viral load was –3·1 log10 copies per mL (–2·5 to –3·6) and in CD4 count 83 cells per μL (40–178). The probability of remaining alive or free of new AIDS-defining events was 0·85 (95% CI 0·73–0·92). Frequency of disease progression was 32·0 (95% CI 16·6–61·5), severe adverse effects 17·8 (7·4–42·7), and genotypic resistance mutations 7·1 (1·8–28·4) per 100 person-years. Mean reported adherence rate was 99%. Median drug concentrations in tablets were 96% of expected values for nevirapine, 89% for stavudine, and 99% for lamivudine. Interpretation Our findings lend support to use and funding of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine as first-line antiretroviral treatment in developing countries." @default.
• W2117579170 created "2016-06-24" @default.
• W2117579170 creator A5011479029 @default.
• W2117579170 creator A5013575025 @default.
• W2117579170 creator A5015663884 @default.
• W2117579170 creator A5019420404 @default.
• W2117579170 creator A5028650786 @default.
• W2117579170 creator A5039710823 @default.
• W2117579170 creator A5041049620 @default.
• W2117579170 creator A5041069033 @default.
• W2117579170 creator A5043125361 @default.
• W2117579170 creator A5053162399 @default.
• W2117579170 creator A5058617930 @default.
• W2117579170 creator A5059371192 @default.
• W2117579170 creator A5061527531 @default.
• W2117579170 creator A5070367150 @default.
• W2117579170 creator A5071700365 @default.
• W2117579170 creator A5076663213 @default.
• W2117579170 creator A5080065932 @default.
• W2117579170 creator A5086419009 @default.
• W2117579170 creator A5089629404 @default.
• W2117579170 date "2004-07-01" @default.
• W2117579170 modified "2023-10-17" @default.
• W2117579170 title "Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial" @default.
• W2117579170 cites W1965550167 @default.
• W2117579170 cites W1977123905 @default.
• W2117579170 cites W1984254136 @default.
• W2117579170 cites W1987858510 @default.
• W2117579170 cites W2007683884 @default.
• W2117579170 cites W2013907757 @default.
• W2117579170 cites W2017793579 @default.
• W2117579170 cites W2018687008 @default.
• W2117579170 cites W2020705331 @default.
• W2117579170 cites W2044854544 @default.
• W2117579170 cites W2050187911 @default.
• W2117579170 cites W2054322922 @default.
• W2117579170 cites W2060210961 @default.
• W2117579170 cites W2061682103 @default.
• W2117579170 cites W2067729283 @default.
• W2117579170 cites W2071683523 @default.
• W2117579170 cites W2092779454 @default.
• W2117579170 cites W2094514022 @default.
• W2117579170 cites W2096035344 @default.
• W2117579170 cites W2141776019 @default.
• W2117579170 cites W2163828009 @default.
• W2117579170 cites W2339219218 @default.
• W2117579170 doi "https://doi.org/10.1016/s0140-6736(04)16586-0" @default.
• W2117579170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15234853" @default.
• W2117579170 hasPublicationYear "2004" @default.
• W2117579170 type Work @default.
• W2117579170 sameAs 2117579170 @default.
• W2117579170 citedByCount "281" @default.
• W2117579170 countsByYear W21175791702012 @default.
• W2117579170 countsByYear W21175791702013 @default.
• W2117579170 countsByYear W21175791702014 @default.
• W2117579170 countsByYear W21175791702015 @default.
• W2117579170 countsByYear W21175791702016 @default.
• W2117579170 countsByYear W21175791702017 @default.
• W2117579170 countsByYear W21175791702018 @default.
• W2117579170 countsByYear W21175791702019 @default.
• W2117579170 countsByYear W21175791702020 @default.
• W2117579170 countsByYear W21175791702021 @default.
• W2117579170 countsByYear W21175791702022 @default.
• W2117579170 crossrefType "journal-article" @default.
• W2117579170 hasAuthorship W2117579170A5011479029 @default.
• W2117579170 hasAuthorship W2117579170A5013575025 @default.
• W2117579170 hasAuthorship W2117579170A5015663884 @default.
• W2117579170 hasAuthorship W2117579170A5019420404 @default.
• W2117579170 hasAuthorship W2117579170A5028650786 @default.
• W2117579170 hasAuthorship W2117579170A5039710823 @default.
• W2117579170 hasAuthorship W2117579170A5041049620 @default.
• W2117579170 hasAuthorship W2117579170A5041069033 @default.
• W2117579170 hasAuthorship W2117579170A5043125361 @default.
• W2117579170 hasAuthorship W2117579170A5053162399 @default.
• W2117579170 hasAuthorship W2117579170A5058617930 @default.
• W2117579170 hasAuthorship W2117579170A5059371192 @default.
• W2117579170 hasAuthorship W2117579170A5061527531 @default.
• W2117579170 hasAuthorship W2117579170A5070367150 @default.
• W2117579170 hasAuthorship W2117579170A5071700365 @default.
• W2117579170 hasAuthorship W2117579170A5076663213 @default.
• W2117579170 hasAuthorship W2117579170A5080065932 @default.
• W2117579170 hasAuthorship W2117579170A5086419009 @default.
• W2117579170 hasAuthorship W2117579170A5089629404 @default.
• W2117579170 hasConcept C126322002 @default.
• W2117579170 hasConcept C141071460 @default.
• W2117579170 hasConcept C142462285 @default.
• W2117579170 hasConcept C197934379 @default.
• W2117579170 hasConcept C203014093 @default.
• W2117579170 hasConcept C2522874641 @default.
• W2117579170 hasConcept C2776623344 @default.
• W2117579170 hasConcept C2777869810 @default.
• W2117579170 hasConcept C2779130552 @default.
• W2117579170 hasConcept C2779889181 @default.
• W2117579170 hasConcept C2780593183 @default.
• W2117579170 hasConcept C2993143319 @default.
• W2117579170 hasConcept C3013748606 @default.
• W2117579170 hasConcept C71924100 @default.
• W2117579170 hasConcept C90924648 @default.

• next